Topic Listing for Alexion Pharmaceuticals

Ability Net Operating Loss Carry Forwards Reduce Future Ability Net Operating Loss Carryforwards Reduce Future Tax
Absences Illness Accepted
Accounting Share-based Compensation Accounting Stock-based Compensation
Accounts Receivable Acknowledgment
Acute Myocardial Infarction Addendum Purchase Sale Agreement
Additional Commercial Commitments Additional Payments
Address Principal Executive Offices Zip Code Adjustments
Adoption New Accounting Pronouncements Adoption Sfas 123r
Age Related Macular Degeneration Dry Form Amd Aggregated Option Exercises Period End Values
Agreement Other Loan Documents Alexion
Alexion Appoints Andreas Rummelt Board Directors Alexion Licenses Pdls Queen Patents Soliris
Alexion Nasdaqalxn Alexion Pharmaceuticals Announces Closing Public Offering Stock
Alexion Pharmaceuticals Announces Completion Common Stock Offering Alexion Pharmaceuticals Announces Management Change
Alexion Pharmaceuticals Announces Pricing Public Offering Common Stock Alexion Pharmaceuticals Announces Proposed Public Offering Common Stock
Alexion Pharmaceuticals Appoints Ruedi Waeger Board Directors Alexion Pharmaceuticals Appoints Vikas Sinha Senior Vice President
Alexion Pharmaceuticals Forms Europe Sas Alexion Pharmaceuticals Inc
Alexion Pharmaceuticals Pdl Biopharma Resolve Patent Dispute Alexion Pharmaceuticals Prices Offering 2500000 Shares Common Stock
Alexion Pharmaceuticals Provides Update Apex-ami Trial Alexion Pharmaceuticals Reports 2006 Results
Alexion Pharmaceuticals Reports End 2006 Results Alexion Pharmaceuticals Reports Half Results
Alexion Pharmaceuticals Reports Results Alexion Reports 2007 Results
Alexion Reports Full 2009 Results Although Obtained Regulatory Approval Soliris Pnh United States
Amended Restated Credit Agreement Amended Restated Promissory
Amendment Amendment Credit Agreement
Amendment Dated 2007 Amendment Employment Agreement
Amendment Rights Agreement Amendments Articles Incorporation Bylaws Change End
Amendments Settlement Agreement Waiver Amounts Except Per Share
Amounts Except Share Per Amounts Except Shares Per Share
Amounts Terms Loan Andreas Rummelt
Annual Incentives Bonuses Annual Transition Reports Pursuant Sections Securities Exchange Act
Anti-cd200 Antibody Anti-cd200 Antibody Oncology Programs
Anti-cd200 Monoclonal Antibody Cancer Anti-mbl Antibody
Anti-takeover Provisions Delaware Law Charter Bylaws Stockholders Rights Anti-tpo Receptor Antibody
Antibody Discovery Technology Platform Antibody-mediated Rejection Amr
Antitrust Competition Appendix
Applicable Law Approval 2004 Incentive Plan
Arbitration Procedures Rules Limitation Jurisdiction Assignment
Assignment Alexion Assignment Rents Leases Contracts
Assistance Tax Returns Asthma
Atypical Hemolytic Uremic Syndrome Ahus Audit Committee
Audit Committee Charter Audit Committee Financial Expert
Audit Committee Report Available Information
Background Balance Sheet
Balance Sheet Data Base Salary
Basis Presentation Basis Presentation Principles Consolidation
Because Target Patient Population Soliris Small Not Been Because Target Patient Population Soliris Treatment Pnh Small
Beneficial Ownership Reporting Compliance Between Undersigned
Biodefense Program Board Committee Matters
Board Directors Deems Proposal 1-election Best Interests Stockholders Board Directors Recommends Vote Proposals
Bonus Borrowings Contractual Obligations
Business Business Expenses
Cannot Manufacture Drug Candidates Sufficient Amounts Acceptable Costs Cannot Protect Confidentiality Proprietary Nature Trade Secrets Business
Cannot Protect Confidentiality Proprietary Nature Trade Secrets Other Capital Leases
Capital Stock Capital Structure
Capitalization Inventory Costs Car Allowance
Cash Equivalents Cash Flows Financing Activities
Cash Flows Investing Activities Cash Flows Operating Activities
Casualty Condemnation Catastrophic Antiphospholipid Syndrome Caps
Certain Clinical Trials Completed Date Not Achieved Primary Certain Relationships Related Transactions
Change Changes Internal Control Over Financial Reporting
Charter Audit Committee Cheshire 2007 Alexion Pharmaceuticals Inc Nasdaq Alxn Today
Cheshire 2008 Alexion Pharmaceuticals Inc Nasdaq Alxn Today Cheshire 2009 Alexion Pharmaceuticals Inc Nasdaq Alxn Today
Cheshire Conn 2007 Alexion Pharmaceuticals Inc Nasdaq Alxn Chmp Issues Positive Opinion European Union Fda Review
Clinical Clinical Trials Acute Myocardial Infarction
Clinical Trials Completed Date Not Achieved Primary Endpoints Clinical Trials Coronary Artery Bypass Graft Surgery
Clinical Trials Membranous Nephritis Clinical Trials Pnh
Clinical Trials Rheumatoid Arthritis Clinical Trials-pnh
Clinical Update Co-founder Remains Board Directors
Code Ethics Cold Agglutinin Disease Cad
Collaboration Collaboration Terminated Reduces Commitment Ability Develop Commercialize Pexelizumab
Combinatorial Human Antibody Library Technologies Commercial Commitments
Commitments Contingencies Committee Authority Responsibilities
Committee Membership Procedures Common
Common Stock Compared 2004
Comparison 2005 2004 Comparison 2006 2005
Comparison 2007 Comparison Cumulative Total Return
Compensation Awarded 2007 Compensation Chief Executive Officer
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Stockholders
Compensation Components Compensation Consultant
Compensation Directors Compensation Discussion Analysis
Compensation Philosophy Competition
Competitors Get Marketplace Before Better Cheaper Drugs Not Competitors Get Marketplace Before Better Cheaper Drugs Product
Competitors Get Marketplace Before Better Cheaper Drugs Products Competitors Get Marketplace Before Better Cheaper Drugs Soliris
Complete Accurate Books Records Completely Dependent Single Party Manufacture Commercial Quantities Soliris
Completion Clinical Trials Not Guarantee Advancement Next Phase Completion Enrollment Phase Trials Highlights Recent Events
Completion Payment Performance Guaranty Completion Preclinical Studies Clinical Trials Not Guarantee Advancement
Compliance Quality Committee Components Compensation-general
Comprehensive Income Comprehensive Income Loss
Comprehensive Loss Conclusion
Condensed Consolidated Balance Sheet Data Condensed Consolidated Statements Operations
Conditions Payment Conditions Precedent Credit Extensions
Conference Call Information Conference Call Scheduled 2005 900 Eastern
Conference Call Scheduled Today 2006 900 Eastern- Conference Call Web Cast Information
Conference Call Webcast Information Confidential Information
Confidentiality Press Releases Conflict Interest
Consent Independent Registered Public Accounting Firm Consolidated Balance Sheet Data
Consolidated Financial Statements Consolidated Statements Operations Data
Contacts Contents
Contingency Cost Reallocation Continue Incur Operating Losses Unable Operations
Contract Manufacturers Fail Comply Continuing United States Foreign Contract Research Revenue
Contractual Obligations Controls Procedures
Conversion Notice Convertible Notes
Convertible Notes Payable Convertible Senior Notes
Convertible Subordinated Notes Coronary Artery Bypass Graft Surgery Cardiopulmonary
Corporate Funds Assets Corporate Governance
Corporate Governance Guidelines Corporate Governance Policies
Cost Product Revenues Cost Sales
Costs Associated Exit Disposal Activities Covenants
Covenants Representations Warranties Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Agreement Credit Financial Market Conditions Aggravate Certain Risks Affecting
Critical Accounting Policies Critical Accounting Policies Estimates
Cumulative Total Return Curagen Corporation Agreement Target Discovery
Current Credit Financial Market Conditions Aggravate Certain Risks Currently Entirely Dependent Single Party Manufacture Commercial Quantities
Customers Debt
Deferred Research Development Payments Xoma Ltd Collaboration Deferred Research Development Payments-xoma Ltd Collaboration
Deferred Revenue Defined Benefit Plan
Defined Contribution Plans Definitions
Dendritic Cell Antibodies Dense Deposit Disease Ddd
Departure Directors Principal Officers Election Appointment Depend Heavily Success Lead Product Soliris Was Approved
Dependent Small Number Customers Significant Portion Revenue Loss Deposits Accounts
Derivative Instruments Derivative Instruments Hedging Activities
Description Amended Restated 2004 Incentive Plan Designated Event
Development Agreements Director Compensation
Director Compensation Policy Disclosure Controls Procedures
Disclosures Discrimination Harassment
Distributor Fees District Delaware
Dividend Policy Drug Trials Delayed Achieve Unfavorable Results Delay Unable
Due Diligence Study Duties
Duties Powers Related Relationship Independent Auditors Duties Powers Relating Compliance Oversight
Duties Powers Relating Financial Statements Disclosure Duties Powers Relating Internal Audit Procedures
Earnings Loss Per Share Eps Eculizumab Development Programs
Eculizumab Development Programs Nephrology Eculizumab New Formulation
Effect Final Adverse Decision Procedure Elements Compensation-general
Employee Benefit Plans Employees
Employment Agreement Employment Agreements
End Results Endothelial Involvement
Engagement Entry Material Definitive Agreement
Environmental Indemnity Agreement Equity Awards
Equity Compensation Plan Information Equity Compensation Plan Information Shares
Establishment Accounts Estimates
Estimates Preparation Financial Statements European Application Track Submission 2006
Even Drug Candidates Obtain Regulatory Approval They Not Event Amount Foreign Service Premium Sum Total Annual
Events Default Events Default Remedies
Exact Name Registrant Specified Charter Exclusive Licenses Rights Granted Pdl Party Prior Effective
Executive Compensation Executive Compensation Objectives Philosophy
Executive Compensation Philosophy Executive Officers
Exhib312 Exhibits
Exit Activities Expand Business Through Acquisitions Disrupt Harm Financial Condition
Expand Business Through Acquisitions In-licensing Opportunities Disrupt Harm Expand Business Through New Acquisitions Disrupt Harm Financial
Expanding Access Soliris Patients Pnh Additional Countries Explanatory
Exposure Additional Tax Liabilities Material Impact Results Operations Facilities
Fail Comply Continuing United States Foreign Regulations Lose Fail Obtain Capital Necessary Fund Operations Unable Continue
Fail Recruit Retain Personnel Not Able Implement Business Fail Recruit Retain Personnel Research Product Development Programs
Fair Value Financial Instruments Fair Value Measurement
Fast Track Designation Federal Income Tax Implications Amended Restated 2004 Incentive
Fees Filing Dow Facility Agreements Considered
Financial Guidance Financial Highlights
Financial Instruments Financial Results
Financial Statements Exhibits Financial Statements Supplementary Data
Financing Activities Following Table Sets Forth Aggregate Fees Billed Pricewaterhousecoopers
Foreign Currency Translation Foreign Exchange Market Risk
Foreign Regulation Foreign Service Premium
Form 10-k Form 10-q
Former Name Address Changed Since Last Report Forward Looking Statement
Full 2007 Financial Results Full 2008 Financial Results
Full 2009 Gaap Financial Results Full 2009 Non-gaap Financial Results
Future Pdl Queen Patent Family Challenges Gaap Financial Results
General Administrative Expenses General Duties Powers
General Information Board Directors Goodwill
Government Regulation Grant
Grants Plan-based Awards Guaranty
Had History Losses Cannot Guarantee Achieve Financial Goals Had History Losses Incur Future
Had History Losses Not Able Achieve Maintain Profitability Had History Losses Not Able Maintain Profitability Quarterly
Healthcare Reform Measures Adversely Affect Business Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Highlighted Fda Approval Soliris Patients Pnh Highlights
Historic Grant Rates Householding Proxy Materials
Immediate Release Immune System
Important Please Sign Exactly Name Appears Below Each Inability Contract Third-party Manufacturers Commercially Reasonable Terms Failure
Incentive Plan Incentive Plan Restricted Stock
Incentive Plan Stock Options Including Eculizumab Indications Other Pnh
Income Taxes Indemnity Contribution
Indenture Independent Registered Public Accounting Firm
Index Index Exhibits
Inhibitor Immunotherapeutic Product Candidates Inhibitors
Intangible Assets Intellectual Property
Intellectual Property Provisions Intentionally Omitted
Interest Expense Interest Rate Market Risk
Interest Rate Risk Internal Control Over Financial Reporting
International Sales Operations Subject Economic Political Legal Business Introduction
Inventions Inventories
Inventory Write-offs Investing Activities
Knotter Drive Cheshire Connecticut 06410 Last End Option Values
Lead Eculizumab Indication Lead Pexelizumab Indications
Lead Program-acute Humoral Rejection Ahr Presensitized Kidney Transplant Lead Program-atypical Hemolytic Uremic Syndrome Ahus
Leases Rents Security Agreement Fixture Filing Legal Proceedings
License Agreements License Assignment
License Patent Rights License Research Development Agreements
Liquidity Liquidity Capital Resources
Liquidity Capital Resources Amounts Except Per Share Data Litigation
Loan Security Agreement Local Law Provisions
Long-lived Assets Long-term Debt
Long-term Incentive Awards Lonza Agreement
Managements Annual Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Manufacturers Fail Comply Continuing United States Foreign Regulations Manufacturing
Manufacturing Facility Market Registrants Common Equity Related Stockholder Matters Issuer
Market Soliris Manner Violates Health Care Fraud Abuse Marketable Securities
Marketing Approval Matters Relating Common Stock
Mayo Clinic Membership Audit Committee
Membranous Nephritis Method Calculation
Miscellaneous Mortgage Debt
Mortgage Loan Mortgage Loan Agreement
Mrc Agreement Multifocal Motor Neuropathy
Multifocal Motor Neuropathy Mmn Myasthenia Gravis
Name Person Filing Proxy Statement Other Registrant Nephrology
Nephrology Atypical Hemolytic Uremic Syndrome Ahus Net Income Loss
Net Loss Net Loss Per Common Share
Net Product Sales Neuromyelitis Optica Nmo
New End News
News Release Contains Forward-looking Statements Including Related Guidance Nominating Governance Committee
Nominees Non-gaap Financial Results
Nonqualified Deferred Compensation Not Able Gain Maintain Market Acceptance Among Medical
Not Able Gain Market Acceptance Among Medical Community Notes Condensed Consolidated Financial Statements
Notes Consolidated Financial Statements Notices
Number 0-27756 Objectives
Off-balance Sheet Arrangements Omrf Alexion
Omrf Obligation Omrf Patents Related Soliris
Oncology Oncology Program
Oncology Program Samalizumab Anti-cd200 Antibody Operating Activities
Operating Leases Option Exercises Stock Vested
Option Grants Five-month Transition Period Option Grants Last
Organization Operations Orphan Drug Designation
Other Business Other Eculizumab Development Programs
Other Events Other Hand
Other Income Expense Other Income Expenses
Other Information Other Licensed Products
Other Long-term Obligation Other Product Candidates
Other Studies Soliris Outlook
Overview Page
Paid Vacation Parcel
Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Pnh
Part Part Other Information
Patents Proprietary Rights Payable
Payments Government Officials Employees Payments Reserve Accounts
Payments Royalties Pdl Biopharma
Pdl Obligation Pdl Queen Patent Family
Peer Group Analysis Pension Benefits
Performance Construction Personal Benefits
Pharmaceutical Healthcare Compliance Laws Regulations Guidance Pharmaceuticals Collaboration
Pipeline Pnh Soliris
Policies Procedures Respect Related Party Transactions Policy
Political Contributions Positive Results Pnh Triumph Phase Study Highlights Period
Pre-approval Policies Procedures Preferred Stock
Prepaid Manufacturing Costs Prepaid Manufacturing Costs Lonza Large-scale Product Supply Agreement
Principal Accountant Fees Services Principles Consolidation
Privacy Prix Galien Award
Prix Galien France Process Selecting Nominees Stockholder Nominations
Procter Gamble Pharmaceuticals Collaboration Product Candidates Except Soliris Received Regulatory Approvals Unable
Product Development Programs Product Revenues Net
Product Sales Product Supply
Products Development Programs Products Harms People Perceived Harm Patients Even Such
Professional Obligations Prohibition Enticement
Properties Property Plant Equipment
Proposal 1-election Directors Proposal 2-amendment 2004 Incentive Plan
Proposal 2-amendment Amended Restated 2004 Incentive Plan Proposal 2-ratification Appointment Independent Registered Public Accounting Firm
Proposal 3-ratification Appointment Independent Registered Public Accounting Firm Proxy Solicitation
Proxy Solicited Board Directors Annual Meeting Stockholders Held Proxy Statement 2007 Annual Report Available
Proxy Statement Pursuant Securities Exchange Act 1934 Purchase Commitments
Purchase Manufacturing Facility Purchase Sale Agreement
Purpose Pursuant General Tax Code
Pursuant Requirements Securities Exchange Act 1934 Registrant Duly Pursuant Requirements Securities Exchange Act 1934 Report Been
Quantitative Qualitative Disclosure Market Risks Quantitative Qualitative Disclosures Market Risk
Ratification Guaranty Reaffirmation Guaranty Environmental Indemnity
Reasons Drug Testing Delayed Terminated Recent Clinical Developments
Recent Developments Recent Events
Recently Issued Accounting Pronouncements Recently Issued Accounting Standards
Recitals Reclassifications
Reclassifications Adjustments Record Date Voting Rights
Regarding Forward-looking Statements Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 203 272-2596 Regulation Disclosure
Regulatory Approval Process Costly Lengthy Not Able Successfully Regulatory Clinical Update Soliris
Regulatory Clinical Update Soliris Eculizumab Reimbursement
Release Parties Remainder Page Intentionally Blank
Remainder Page Intentionally Left Blank Remainder Page Intentionally Left Blank Signature Follows
Remainder Page Left Intentionally Blank Remuneration
Renal Transplantation Rents Security Agreement Fixture Filing
Report Independent Registered Public Accounting Firm Reporting Compliance Concerns Accountability
Representations Warranties Representations Warranties Indemnification
Research Development Research Development Expenses
Research Development Progress Research Rationale
Resignation Vice President Chief Financial Officer Rest Page Intentionally Blank
Restitution Restricted Cash
Restricted Stock Restricted Stock Award Agreement
Restricted Stock Unit Agreement French Participants Results Operations
Results Operations Financial Condition Revenue
Revenue Assets Geography Revenue Recognition
Revenues Revocability Voting Proxy
Revolving Credit Facility Rheumatoid Arthritis
Rights Purchase Junior Participating Cumulative Preferred Stock Par Risk Loss
Risks Related Business Risks Related Common Stock
Risks Related Development Clinical Testing Regulatory Approval Product Risks Related Financial Position Need Additional Capital
Risks Related Intellectual Property Risks Related Lead Product Soliris
Role Compensation Committee Role Executives 2008 Compensation Decisions
Role Executives Compensation Decisions Ropes Gray Llp Letterhead
Royalties Royalties Other Payments Licensed Products
Royalty Reports Safe Harbor Statement
Sale Property Subject Terms Conditions Agreement Basis Representations Sales Marketing
Schedule Schedule 113
Schedule 133 Schedules
Secondary Market Transaction Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Laws Insider Trading
Security Agreement Security Agreement Fixture Filing
Segment Reporting Selected Financial Data
Sellers Disclaimer Representations Warranties Selling General Administrative Expenses
Senior Notes Raising 150 Settlement
Settlement Assignment Agreement Signature
Signature Held Jointly Signature Page Follows
Signatures Significance Mayo Clinic Research
Significantly Leveraged Social Coverage
Soliris Soliris Commercial Update
Soliris Commercial Update International Soliris Commercial Update United States
Soliris Eculizumab Pnh Soliris Eculizumab Reviewed European Accelerated Assessment Procedure
Soliris Harms People Perceived Harm Patients Even Such Soliris Investigational Treatment Patients Other Rare Severe Diseases
Soliris Investigational Treatment Patients Other Ultra-rare Severe Diseases Soliris Product Candidates Harms People Perceived Harm Patients
Soliris Product Launch Soliris Treatment Patients Other Complement-mediated Disorders
Soliris Treatment Patients Other Rare Severe Diseases Soliris Treatment Patients Pnh
Soliris Treatment Patients Rare Severe Diseases Source Supply
Special Bonus Award Stipulation Order Dismissal
Stipulation Order Staying Litigation Stock Based Compensation
Stock Option Agreement Stock Options
Stock Options Restricted Awards Stock Performance
Stock Split Stock-based Compensation
Stockholder Communications Board Directors Stockholder Proposals
Stockholders Held 2009 Strategic Alliance Procter Gamble
Subject Environmental Laws Potential Exposure Liabilities Subject Extensive Government Regulation Not Maintain Regulatory Approval
Subject Extensive Government Regulation Not Maintain Regulatory Approvals Subject Extensive Government Regulation Not Obtain Maintain Regulatory
Subject Extensive Government Regulation Not Obtain Regulatory Approval Sublicense Rights
Submission Matters Vote Security Holders Subsequent Event
Subsequent Events Sufficiency Cash Resources
Supplemental Schedule Noncash Financing Activities Supply Agreement
Table Contents Taxes
Term Termination Termination
Termination Agreement Termination Based Compensation
Testing Products Harms People Subject Costly Damaging Product Therapy Approved Rare Life-threatening Blood Disease
Through Ash Website Title Report Survey
Total Operating Expenses Trading Price Common Stock Continues Fluctuate Wide Range
Transplant Transplant Acute Humoral Kidney Rejection Ahr
Treatment Paroxysmal Nocturnal Hemoglobinuria Trial Period
Tuesday 2009 Unable Engage Retain Third-party Collaborators Research Development Efforts
Unable Establish Maintain Effective Sales Marketing Distribution Capabilities Unable Establish Sales Marketing Distribution Capabilities Enter Agreements
Unable Obtain Maintain Reimbursement Soliris Government Health Administration Unable Obtain Reimbursement Future Products Government Health Administration
Unable Obtain Reimbursement Soliris Government Health Administration Authorities Unigraft Xenotransplantation Technologies Program
United States United States District Court
Unless Boxes Checked Trustee Refuse Register Notes Evidenced Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Valuation Techniques
Waiver Amendment Credit Agreement Waivers Amendments Such Defaulting Lenders Right Approve Disapprove
Washington 20549 Whereas
William Keller Witness Whereof Agreement Been Executed Date Above Written
Witnesseth Work Place
Working Capital Loan Working Time
Xoma Collaboration Xoma Ltd Collaboration
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki